(Q34134297)

31 July 2017

1 reference

title

Cyclooxygenase-2: a major therapeutic advance? (English)

1 reference

31 July 2017

1

Emery P

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 January 2001

1 reference

American Journal of Medicine

31 July 2017

published in

1 reference

31 July 2017

volume

110

1 reference

31 July 2017

issue

1A

1 reference

31 July 2017

page(s)

42S-45S

1 reference

Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900649-5

Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900649-5

COX-2 in synovial tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900649-5

The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900649-5

Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900649-5

Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900649-5

Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900649-5

Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib: a randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900649-5

Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900649-5

Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protoco

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900649-5

Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900649-5

Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900649-5

Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900649-5

Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy M

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900649-5

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900649-5

Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case-control study in Rochester, Minnesota, 1980 through 1984.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900649-5

Angiotensin II attenuates renal cortical cyclooxygenase-2 expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900649-5

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900649-5

10.1016/S0002-9343(00)00649-5

7 January 2021

Identifiers

DOI

1 reference

31 July 2017

1 reference